KPV
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
KPV is not a large molecule. It is three amino acids – lysine, proline, valine – cleaved from the C-terminal end of α-melanocyte-stimulating hormone. That brevity is, in part, the point. The parent peptide, α-MSH, carries broad melanocortin activity across five receptor subtypes. KPV retains a focused subset of that activity: principally at MC1R and MC3R, the receptors most implicated in peripheral and mucosal immune regulation. What the literature describes is a signal that enters inflamed tissue, engages specific receptor architecture, and attenuates the transcriptional machinery driving cytokine production – without the broad immunosuppression that accompanies corticosteroid intervention.
Peptide origin explains why KPV attracts interest disproportionate to its size. It is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone and preserves part of the parent molecule’s anti-inflammatory signaling profile.
Inflammatory control appears to center on suppression of NF-kB dependent transcription. In preclinical systems, KPV reduces mediators such as TNF-alpha, IL-1beta, and IL-6 without acting through glucocorticoid pathways.
Intestinal relevance is where the literature is most developed. Murine colitis models have shown reduced mucosal inflammation after oral, topical, and parenteral delivery, though formulation strongly influences what is feasible.
Translational status remains early. Its small size supports favorable solubility and tissue access, but as of 2026 the evidence base is still predominantly preclinical rather than clinical.
What we observe
Observed gut and skin effects
The outcomes described below reflect patterns reported in pre-clinical and early translational research. KPV has not completed controlled human clinical trials. The observations are drawn from murine colitis models, in vitro cytokine assays, and dermal wound studies. They describe what the literature reports – not what any individual will experience. Aeterna does not prescribe, dispense, or sell.
01
Colonic Inflammation
02
NF kB Suppression
03
Barrier Preservation
04
Wound Closure
05
Cytokine Reduction
06
Oral Delivery
Evidence
Evidence behind KPV
The studies below represent selected entries from a body of pre-clinical literature spanning approximately three decades. KPV’s evidence base is concentrated in animal models and in vitro systems. Human pharmacokinetic and efficacy data remain limited. The literature is cited here for orientation, not as proof of clinical effect.
Anti-inflammatory effects of the C-terminal tripeptide of alpha-melanocyte-stimulating hormone: KPV modulates NF-κB activation in murine macrophages
The founding characterization of KPV’s anti-inflammatory activity. Lipton and Catania demonstrated that the C-terminal tripeptide of α-MSH inhibited LPS-induced NF-κB nuclear translocation in peritoneal macrophages and reduced TNF-α secretion in a dose-dependent manner. The study established that the C-terminal sequence, not the full peptide, was sufficient for anti-inflammatory signaling – a finding that anchored two decades of subsequent fragment research.
Oral delivery of KPV in hydrogel nanoparticles ameliorates intestinal inflammation in a murine model of colitis
Researchers at Emory University encapsulated KPV in PEGylated hydrogel nanoparticles and administered the formulation orally to DSS-treated mice. Colonic inflammation scores, myeloperoxidase activity, and mucosal cytokine levels were significantly reduced relative to free-peptide oral controls, demonstrating that encapsulation protected KPV from gastric degradation and enabled targeted mucosal delivery. Tight-junction protein expression was preserved in treated animals.
KPV accelerates cutaneous wound healing through MC1R-mediated TGF-β1 upregulation in dermal fibroblasts
A murine excisional wound model demonstrated that topical KPV application twice daily accelerated wound closure compared to vehicle controls, with histological analysis confirming increased collagen density and earlier re-epithelialization. Mechanistic assays identified MC1R as the primary receptor mediating the effect, with downstream upregulation of TGF-β1 and VEGF in wound-margin fibroblasts. The study proposed KPV as a candidate for dermal repair applications where inflammation and healing overlap.
From lyophilized powder to a usable solution.
Peptide
10 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
3.33 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 200–500 mcg once daily (gradual titration recommended)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F) or below.
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.
- Avoid freeze–thaw cycles.
- KPV's small molecular weight makes it susceptible to adsorption onto certain plastics; use low-binding polypropylene vials and syringes where possible
- Do not expose reconstituted solution to temperatures above 25 °C for extended periods; peptide degradation accelerates significantly above this threshold
Side effects
What members describe
- Injection-site reactions - mild erythema or transient discomfort - have been noted in subcutaneous administration protocols; typically self-resolving within hours
- KPV's melanocortin receptor activity is selective for MC1R and MC3R; melanotropic effects (skin pigmentation changes) associated with MC1R agonism are theoretically possible but have not been prominently reported at research doses
- Transient fatigue or mild nausea has been anecdotally reported in researcher self-administration contexts; causality has not been established in controlled studies
- Given its immunomodulatory mechanism, theoretical concern exists regarding altered immune surveillance with prolonged use; the literature does not report opportunistic infections in pre-clinical models, but long-term human data are absent
- No significant cardiovascular or hepatic adverse signals have emerged in pre-clinical literature at doses studied to date
Contradictions
Reasons to abstain
- Known hypersensitivity to any melanocortin peptide or to any component of the formulation
- Active malignancy, particularly melanoma or other MC1R-expressing tumors, until the effect of MC1R agonism on tumor biology is better characterized
- Pregnancy and lactation - no safety data exist; use is not appropriate outside controlled research settings
- Concurrent use of immunosuppressive agents - additive immunomodulatory effects have not been studied and cannot be predicted from available literature
- Individuals with autoimmune conditions managed by active immune surveillance should approach any immunomodulatory peptide with caution and under direct physician oversight
Synergies
Useful partners for KPV
KPV’s primary axis is mucosal and systemic inflammation. Its companions in research protocols tend to address overlapping pillars: gut barrier integrity, tissue repair, and immune regulation. The combinations below reflect patterns observed in the literature and in researcher-reported protocols – not clinical recommendations. Aeterna does not prescribe, dispense, or sell.
FAQ
Your questions, patiently answered
KPV – lysine-proline-valine – is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). The parent peptide, α-MSH, is a 13-amino-acid neuropeptide with broad melanocortin activity spanning pigmentation, appetite regulation, and immune modulation. Research in the 1990s established that the C-terminal sequence alone retained significant anti-inflammatory activity, leading to KPV’s characterization as a minimal active fragment. It is not a synthetic invention but a structural derivative of an endogenous signaling molecule.
Most anti-inflammatory peptides operate through broad cytokine suppression or corticosteroid-adjacent pathways that carry immunosuppressive risk. KPV’s mechanism is more targeted: it engages MC1R and MC3R to attenuate NF-κB transcriptional activity without inducing widespread immune cell apoptosis or suppressing adaptive immunity. Its small size – three amino acids – also distinguishes it practically, enabling delivery routes (oral, topical) that larger peptides cannot reliably achieve without specialized formulation.
Unencapsulated oral KPV is largely degraded by gastric proteases before reaching the colon. The literature’s answer to this problem is encapsulation: PLGA nanoparticles and PEGylated hydrogel systems have demonstrated the ability to protect KPV through the gastric environment and release it at the colonic mucosa. In murine models, encapsulated oral KPV has produced outcomes comparable to subcutaneous administration. Whether this translates to human pharmacokinetics remains an open question – the formulation science is promising but not yet clinically validated.
The published literature concentrates on two primary areas: intestinal inflammation (DSS-induced and TNBS-induced colitis in murine models, with relevance to IBD) and dermal wound healing. Secondary literature addresses systemic inflammatory states, including sepsis-adjacent models, and neuroinflammation – where KPV’s ability to cross certain epithelial barriers raises questions about CNS access. The evidence base is pre-clinical; no completed human clinical trials have been published as of 2025.
MC1R is the primary receptor governing eumelanin production in melanocytes. KPV’s agonist activity at MC1R raises a theoretical concern about melanotropic effects – the same concern that applies to α-MSH and its analogues. In practice, the pre-clinical literature does not prominently report pigmentation changes at anti-inflammatory research doses, possibly because KPV’s affinity and efficacy at MC1R are lower than those of full-length α-MSH or potent synthetic analogues like Melanotan II. The question has not been systematically studied in humans.
This monograph is the primary entry point. It situates KPV within the melanocortin signaling vocabulary, maps its receptor pharmacology, and surveys the pre-clinical evidence base. Aeterna’s practice translates the science – it does not prescribe, dispense, or sell. Readers seeking to apply this knowledge in a clinical context are directed to work with a qualified physician who can evaluate individual circumstances against the available literature.
In the same family
Adjacent entries in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.